Results 191 to 200 of about 46,851 (215)

Anti‐PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT‐like and VITT‐like characteristics

British Journal of Haematology, EarlyView.
Summary Vaccine‐induced immune thrombocytopenia and thrombosis (VITT) is one of several anti‐platelet factor 4 (anti‐PF4)‐associated immune thrombocytopenia and thrombosis (PITT) syndromes. As well as following adenoviral vector vaccines, VITT has recently been described following acute adenovirus infection.
Phillip L. R. Nicolson, Samantha J. Montague, Richard J. Buka, Anthony Calvert, Jo‐Ann I. Sheppard, Yi Zhang, Jing Jing Wang, Jack Sharman, Eman Hassan, James Harrison, Errin Lawrence, Phillip El‐Dalil, Dhruv Parekh, Husam Osman, Tom P. Gordon, Ishac Nazy, Theodore E. Warkentin, Will A. Lester   +17 more
wiley   +1 more source

ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system

British Journal of Pharmacology, EarlyView.
G protein‐coupled receptors (GPCRs) are a large family of cell surface receptors that play a critical role in nervous system function by transmitting signals between cells and their environment. They are involved in many, if not all, nervous system processes, and their dysfunction has been linked to various neurological disorders representing important
Necla Birgül Iyison, Clauda Abboud, Dayana Abboud, Abdulrasheed O. Abdulrahman, Ana‐Nicoleta Bondar, Julie Dam, Zafiroula Georgoussi, Jesús Giraldo, Anemari Horvat, Christos Karoussiotis, Alba Paz‐Castro, Miriam Scarpa, Hannes Schihada, Nicole Scholz, Bilge Güvenc Tuna, Nina Vardjan   +15 more
wiley   +1 more source

P2Y14 receptor activation of platelets induces Ca2+ mobilization and Rho‐GTPase‐dependent motility that requires an interaction with P2Y1 receptors

British Journal of Pharmacology, EarlyView.
Background and Purpose Platelet function during inflammation is dependent on activation by endogenous nucleotides acting on purinergic receptors. The P2Y14 receptor has been reported to be expressed on platelets and is involved in leukocyte recruitment during inflammation.
Md Monir Hossain, Dingxin Pan, Kate L. Arkless, Khondaker Miraz Rahman, Clive P. Page, Kalwant S. Authi, Simon C. Pitchford   +6 more
wiley   +1 more source

High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The C‐type lectin‐like receptor‐2 (CLEC‐2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis.
Marcin A. Sowa, Yan Wu, Jan van Groningen, Ying Di, Helma van den Hurk, Johannes A. Eble, Jonathan M. Gibbins, Ángel García, Alice Y. Pollitt   +8 more
wiley   +1 more source

Nimodipine reduces microglial activation in vitro as evidenced by morphological phenotype, phagocytic activity and high‐throughput RNA sequencing

British Journal of Pharmacology, EarlyView.
Background and Purpose Nimodipine, an L‐type voltage‐gated calcium channel blocker, is an approved cerebral vasorelaxant. We hypothesized that nimodipine attenuates the pro‐inflammatory shift in microglial phenotypes. Here, we analysed the effects of nimodipine on morphological and functional microglial phenotypes as well as their transcriptomic ...
István Pesti, Valentin Varga, Erda Qorri, Rita Frank, Diana Kata, Krisztián Vinga, Péter Archibald Szarvas, Ákos Menyhárt, Károly Gulya, Ferenc Bari, Eszter Farkas   +10 more
wiley   +1 more source

Role of the RAB27/SYTL Axis in Tumor Microenvironment Construction

Cancer Science, EarlyView.
This review focuses on the role of the RAB27/SYTL axis in various cancer types associated with tumor microenvironment modifications. The importance of this pathway and the potential therapeutic strategies targeting vesicle production for the treatment of cancer are also discussed.
Miwa Tanaka, Takuro Nakamura
wiley   +1 more source

Mesenchymal Stem Cell‐Derived Exosomes: A Promising Therapeutic Strategy for Age‐Related Diseases

Cell Proliferation, EarlyView.
Mechanisms of MSC‐Exos in the treatment of age‐related diseases. A Immunomodulatory and anti‐inflammatory, MSC‐Exos mediate immunomodulatory and anti‐inflammatory effects by regulating the polarisation of T cells and macrophages, promoting an anti‐inflammatory state while inhibiting pro‐inflammatory responses; B Suppression of oxidative stress, MSC ...
Bohua Wei, Mengting Wei, Haonan Huang, Ting Fan, Zhichang Zhang, Xiaoyu Song   +5 more
wiley   +1 more source

Dual Role of Natural Killer Cells in Early Pregnancy: Immunopathological Implications and Therapeutic Potential in Recurrent Spontaneous Abortion and Recurrent Implantation Failure

Cell Proliferation, EarlyView.
This article elaborates on the role of NK cells in early pregnancy from multiple perspectives, including molecular mechanisms and therapeutic interventions. It also discusses how NK cell dysfunction contributes to RSA and RIF, aiming to provide insights for future research on NK cell mechanisms and clinical treatment of RSA and RIF.
Defeng Guan, Zhou Chen, Yuhua Zhang, Wenjie Sun, Lifei Li, Xia Huang   +5 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Platelet-Rich Plasma

Physical Medicine and Rehabilitation Clinics of North America, 2016
Platelet-rich plasma (PRP) is a growing and robust therapeutic option in musculoskeletal medicine. PRP is a preparation of autologous plasma enriched with a platelet concentration above that normally contained in whole blood. The rationale for use and therapeutic potential of a high concentration of platelets is based on their capacity to supply ...
Robert Diaz, Peter I-Kung Wu, Joanne Borg-Stein   +2 more
openaire   +4 more sources

Platelet-Rich Plasma

Clinics in Sports Medicine, 2019
Platelet-rich plasma (PRP) is a promising treatment for musculoskeletal maladies and clinical data to date have shown that PRP is safe. However, evidence of its efficacy has been mixed and highly variable depending on the specific indication. Additional future high-quality large clinical trials will be critical in shaping our perspective of this ...
Jason L. Dragoo, Adrian D.K. Le, Malcolm R. DeBaun, Lawrence Enweze   +3 more
openaire   +5 more sources